Everest Medicines (HKSE:01952) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jan. 18, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Everest Medicines's float shares is 0.00 Mil. Everest Medicines's total shares outstanding is 322.29 Mil. Everest Medicines's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Everest Medicines's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Everest Medicines's Institutional Ownership is 5.69%.

Everest Medicines Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Everest Medicines's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.00	/	322.29
	=	0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Everest Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Executives

Fu Wei	2307 Founder of a discretionary trust who can infl
Nova Aqua Limited	2201 Interest of corporation controlled by you
C-bridge Joint Value Creation Limited	2201 Interest of corporation controlled by you
Everest Management Holding Co., Ltd.	2101 Beneficial owner
Ra Capital Management, L.p.	2102 Investment manager
Kolchinsky Peter	2305 Beneficiary of a trust
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Fu Wei	2307 Founder of a discretionary trust who can infl
Janchor Partners Limited	2102 Investment manager
C-bridge Capital Gp, Ltd.	2501 Other
Vistra Trust (singapore) Pte. Limited	2501 Other
C-bridge Capital Gp Iv, Ltd.	2201 Interest of corporation controlled by you
C-bridge Iv Investment Nine Limited	2101 Beneficial owner

Everest Medicines Headlines

No Headlines